Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Oct 20, 2022 3:19pm

107 Views

Post# 35037203

AGN to present @ Wonderland Psychedelic Medicine Conference

Dr. Rick Strassman, AGN consultant and author of DMT: The Spirit Molecule will join Algernon Pharmaceuticals' (AGN.c AGNPF) CEO for a keynote address at the Wonderland Psychedelic Medicine event.

Their address is happening on Nov 5 at 2pm EST.

In it, they will discuss AGN's clinical study on using DMT to treat stroke survivors.

https://www.benzinga.com/pressreleases/22/10/g29266283/algernon-pharmaceuticals-announces-dr-rick-strassman-author-of-dmt-the-spirit-molecule-to-join-ceo

AGN @ $2.82, MC $6.649M

<< Previous

Bullboard Posts

Next >>

Two Venture-listed mining stocks file NI 43-101 reports